This app is meant to be used only by physicians and it is not meant
to make clinical decisions (the clinical usefulness of the two
models has not been tested) but to be used as an informative tool
to improve the predictive capability of a physician.
Two kinds of predictions are possible:
- RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. .
- STS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.
Two kinds of predictions are possible:
- RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. .
- STS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.
SARCULATOR / What's New in vUnknown
Update: new model for patients with primary RPS taking into
consideration the improved outcome over time and the case-volume
effect.
Aggiornamento: nuovo modello per pazienti con sarcomi primitivi del retroperitoneo che tiene in considerazione del miglioramento della prognosi osservata negli anni recenti e l’effetto del volume del centro.
Aggiornamento: nuovo modello per pazienti con sarcomi primitivi del retroperitoneo che tiene in considerazione del miglioramento della prognosi osservata negli anni recenti e l’effetto del volume del centro.